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Abstract
Objectives The aims of this study were to develop a
population pharmacokinetic model for intravenous parac-
etamol in preterm and term neonates and to assess the
generalizability of the model by testing its predictive per-
formance in an external dataset.
Methods Nonlinear mixed-effects models were con-
structed from paracetamol concentration–time data in
NONMEM 7.2. Potential covariates included body weight,
gestational age, postnatal age, postmenstrual age, sex, race,
total bilirubin, and estimated glomerular filtration rate. An
external dataset was used to test the predictive performance
of the model through calculation of bias, precision, and
normalized prediction distribution errors.
Results The model-building dataset included 260 obser-
vations from 35 neonates with a mean gestational age of
33.6 weeks [standard deviation (SD) 6.6]. Data were well-
described by a one-compartment model with first-order
elimination. Weight predicted paracetamol clearance and
volume of distribution, which were estimated as 0.348 L/h
(5.5 % relative standard error; 30.8 % coefficient of vari-
ation) and 2.46 L (3.5 % relative standard error; 14.3 %
coefficient of variation), respectively, at the mean subject
weight of 2.30 kg. An external evaluation was performed
on an independent dataset that included 436 observations
from 60 neonates with a mean gestational age of
35.6 weeks (SD 4.3). The median prediction error was
10.1 % [95 % confidence interval (CI) 6.1–14.3] and the
median absolute prediction error was 25.3 % (95 % CI
23.1–28.1).
Conclusions Weight predicted intravenous paracetamol
pharmacokinetics in neonates ranging from extreme
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preterm to full-term gestational status. External evaluation
suggested that these findings should be generalizable to
other similar patient populations.
Key Points
In neonates ranging from extreme preterm to full-
term gestational status, body weight is the principal
predictor of intravenous paracetamol
pharmacokinetics.
A parsimonious regimen based only on equivalent
per kilogram doses may be sufficient to
accommodate maturational changes in paracetamol
pharmacokinetics, even for extremely preterm
neonates; however, additional studies are needed to
ensure that such a simplified dosing regimen does
not increase the risk of paracetamol-induced
hepatotoxicity in any neonatal subpopulations.
1 Introduction
Inadequate management of neonatal pain is associated with
poor short- and long-term neurodevelopmental outcomes
[1]. In neonates and infants, mild to moderate pain is
commonly treated with paracetamol (N-acetyl-p-
aminophenol, acetaminophen) [2, 3]. Although paracetamol
has been widely used for nearly a century, intravenous
formulations only became available recently [4], with reg-
ulatory approval for use in patients aged 2 years or older
occurring as late as 2010 in the case of the US [5]. Intra-
venous paracetamol has rapidly gained favor for applica-
tions in which enteral delivery is not possible, such as
postoperative pain relief [4], and several recent studies have
reported on the pharmacokinetics of intravenous paraceta-
mol in neonates [6–8]. However, there is still a lack of
consensus regarding optimal dosing guidelines [3, 6, 9–11]
and, in many cases, administration of intravenous parac-
etamol to neonates is limited to off-label use [3]. Further-
more, pharmacokinetic data from extremely preterm
neonates (\28 weeks’ gestation) remain scarce [3, 6, 8].
Appropriate dose selection for neonates is complicated
by developmental changes that occur during early life [12].
Paracetamol is primarily eliminated by hepatic metabo-
lism; therefore, measures of hepatic maturation and func-
tion are critical for explanation of between-subject
variability (BSV) in paracetamol pharmacokinetics [6–8,
13, 14]. Population pharmacokinetic modeling is a pow-
erful tool for analyzing sparse neonatal data because the
approach simultaneously utilizes information from all
subjects to characterize the study population, BSV, and
influential patient characteristics (covariates) [15, 16].
Unfortunately, neonatal population pharmacokinetic stud-
ies are frequently limited by small numbers of subjects.
Ideally, the external generalizability of population phar-
macokinetic models should be evaluated with independent
data that were not used in model development; however,
due to a paucity of neonatal studies, this is rarely possible
[15–18].
The aims of this study were to develop a population
pharmacokinetic model for intravenous paracetamol in
preterm and term neonates, and to assess generalizability of
the model by testing its predictive performance when
applied to an external dataset.
2 Methods
2.1 Study 1: Model-Building Dataset
2.1.1 Ethics Approval and Study Registration
This was a prospective, single-center, open-label study of
the pharmacokinetics of intravenous paracetamol in neo-
nates. The study was approved by the Institutional Review
Board at the Children’s National Health System (Wash-
ington, DC, USA) and was carried out in concordance with
International Conference on Harmonisation (ICH) Guide-
lines for Good Clinical Practice [19]. The study was reg-
istered at ClinicalTrials.gov (NCT01328808) [20].
2.1.2 Study Population
Patients\28 days postnatal age with an indwelling arterial
line and a clinical indication for intravenous analgesia who
were admitted to intensive care units at the Children’s
National Health System (Washington, DC, USA) were
considered for inclusion. Exclusion criteria were severe
asphyxia, grade III or IV intraventricular hemorrhage,
major congenital malformations, neurological disorders,
receipt of neuromuscular blockers, and hepatic or renal
failure, including systemic hypoperfusion.
2.1.3 Dosing and Sampling Schedule
Intravenous paracetamol (Ofirmev, 10 mg/mL; Mallinck-
rodt Pharmaceuticals, Dublin, Ireland) was administered by
30-min infusions at 15 mg/kg/dose. The dosing schedule
was based on gestational age. Neonates \28 weeks’ ges-
tation received five doses at 12-h intervals; neonates C28
weeks’ gestation received seven doses at 8-h intervals.
Blood samples (0.2 mL) were obtained from arterial lines
at approximately 0, 1, 2, 4, 6, 8, 12, and 24 h after the first
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and last paracetamol doses. Patients were randomly
assigned to one of two sampling schedules, each consisting
of 9–10 collection times. Blood was collected in sodium
heparin Vacutainer tubes (BD, Franklin Lakes, NJ, USA)
and centrifuged for 10–15 min at 15009g at 4 C. Plasma
was transferred to cryovials and stored at -70 F. Study
samples were shipped on dry ice to the Center for Human
Toxicology at the University of Utah, and stored at -80 C
prior to analysis.
2.1.4 Analytical Method
Paracetamol plasma concentrations were determined using
high-performance liquid chromatography–tandem mass
spectrometry (HPLC–MS/MS). Plasma samples (10 lL)
were fortified with paracetamol-d4 internal standard (Tor-
onto Research Chemicals, Toronto, ON, Canada) and pre-
pared using protein precipitation with acetonitrile (600 lL).
Sample supernatants were evaporated to dryness and
reconstituted in 0.1 % aqueous formic acid (400 lL).
Reconstituted samples were injected (100 lL) onto an
Agilent 1260 Infinity HPLC system interfaced with an
Agilent 6460 triple-quadrupole mass spectrometer (Agilent
Technologies, Santa Clara, CA, USA). The autosampler
was maintained at 5 C, and the autosampler needle was
washed with methanol/water (1/1, v/v) between injections.
Chromatographic separation was achieved with an Agilent
Poroshell 120 EC-C18 column (2.1 9 100 mm, 2.7 lm
particle size; Agilent Technologies, Santa Clara, CA, USA)
maintained at 40 C using a gradient mobile phase con-
sisting of 10 mM aqueous ammonium acetate, pH 3.5
(A) and methanol (B) at a flow rate of 0.25 mL/min. Mobile
phase was maintained at 3 % B for 6 min, increased linearly
to 35 % B over 3 min, maintained at 95 % B for 3 min,
decreased linearly to 3 % B over 0.5 min, and re-equili-
brated at 3 % B for 7.5 min. The mass spectrometer was
operated in positive electrospray ionization ? Agilent Jet
Stream mode with multiple reaction monitoring (MRM).
The following settings were applied: 350 C gas tempera-
ture, 10 L/min gas flow, 30 psi nebulizer pressure, 350 C
sheath gas temperature, 9 L/min sheath gas flow, 3500 V
capillary voltage, 500 V nozzle voltage, 250 V delta EMV,
80 V fragmentor voltage, 14 V collision energy, and
100 ms dwell time. MRM transitions for paracetamol and
paracetamol-d4 were 152.1 ? 110.0 and 156.1 ? 114.1
(precursor ? product m/z), respectively.
The lower limit of quantification (LLOQ) was 0.05 mg/
L [mean accuracy 92 %, coefficient of variation (CV)
5.3 %, n = 6], and the calibration curve maintained lin-
earity up to 50 mg/L (1/x2 weighting). Triplicate sets of
quality control samples at concentrations of 0.15, 0.80, 8.0,
and 40 mg/L accompanied each study sample batch. At
these concentrations, mean intra-assay (n = 5) and inter-
assay (n = 20) accuracy ranged from 98 to 104 %, and
intra- and inter-assay imprecision was\10 % CV.
2.2 Study 2: External Evaluation Dataset
2.2.1 Ethics Approval and Study Registration
Data for external model evaluation were obtained from a
previously published, prospective, single-center, open-la-
bel study on the pharmacokinetics of intravenous parac-
etamol in neonates (PARANEO) [6]. The study was
approved by the Ethics Committee at University Hospitals
Leuven (Leuven, Belgium) and was carried out in con-
cordance with ICH Guidelines for Good Clinical Practice
[19]. The study was registered at ClinicalTrials.gov
(NCT00969176) [21] and with the European Clinical Trials
Database (EUdraCT) (2009-011243-39).
2.2.2 Study Population
Patients B28 days postnatal age with a clinical indication
for intravenous paracetamol who were admitted to the
Neonatal Intensive Care Unit at University Hospitals
Leuven (Leuven, Belgium) were considered for inclusion.
Exclusion criteria were recent receipt of paracetamol
(\48 h) or clinical contraindication for paracetamol
administration (i.e. hepatic failure).
2.2.3 Dosing and Sampling Schedule
Intravenous paracetamol (10 mg/mL; Sintetica SA, Men-
drisio, Switzerland) was administered by 15-min infusions
with a loading dose of 20 mg/kg, followed by up to seven
maintenance doses at 6-h intervals. Each maintenance dose
consisted of 5.0, 7.5, or 10.0 mg/kg, respectively, for neo-
nates with postmenstrual ages\32, 32–36, or[36 weeks.
Samples were obtained from an arterial line over the 48 h
following paracetamol loading doses. The sampling
schedule focused on the periods shortly after each loading
dose (\2 h; peak concentrations) and just before mainte-
nance doses (5–6 h after the previous dose; trough con-
centrations). Blood was centrifuged, and plasma samples
were stored at -20 C until analysis.
2.2.4 Analytical Method
Paracetamol plasma concentrations were determined using
HPLC coupled with ultraviolet detection. Details of the
analytical method have been previously reported [22]. The
LLOQ was 0.08 mg/L (\20 % CV), and intra- and interday
imprecision was\15 % CV.
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2.3 Pharmacometric Model Development
The paracetamol pharmacokinetic model was developed in
NONMEM (nonlinear mixed-effects modeling) 7.2 inter-
faced with PDx-Pop 5.0 (ICON Development Solutions,
Ellicott City, MD, USA) using the first-order conditional
estimation with interaction method. Processing and visu-
alization of NONMEM output were performed in R 3.0.1
(CRAN.R-project.org). Throughout model development,
standard diagnostic plots were generated to evaluate model
fit, including observed concentrations versus population-
and individual-predicted concentrations, conditional
weighted residuals versus time and population-predicted
concentrations, and histograms of individual random
effects. Models were also compared based on the precision
of parameter estimates (parametric standard errors) and
condition number [23]. Hierarchical models were com-
pared using the objective function value (OFV). Non-
hierarchical models were compared using the Bayesian
Information Criterion (BIC) [24].
Based on visual data inspection and a review of the
literature, one- and two-compartment structural models
were considered. Models were parameterized with clear-
ance and volume terms. Structural models also incorpo-
rated the rate and duration of intravenous paracetamol
infusion for each dose. Random effects were classified as
either between-subject variability (BSV) or residual unex-
plained variability (RUV). Individual pharmacokinetic
parameters were assumed to be log-normally distributed,
and BSV was modeled with an exponential function
(Eq. 1):
hi ¼ hpop  egi ð1Þ
where hi is the individual model-predicted pharmacokinetic
parameter (e.g. clearance), hpop is the population mean for
the pharmacokinetic parameter h, and gi is the between-
subject random effect on h for the ith individual; gi is
normally distributed with a mean of zero and a variance of
x2. Additive, proportional, and combined additive and
proportional functions were tested for incorporation of
RUV [25].
Potential covariates included current body weight, cur-
rent body length, current body mass index (BMI), gesta-
tional age, postnatal age, postmenstrual age, total bilirubin,
estimated glomerular filtration rate (GFR), sex, race
(White/Caucasian or Black/African American), ethnicity,
and indication (surgical or procedural). Laboratory samples
were obtained within 24 h prior to the first paracetamol
dose or during the pharmacokinetic sample collection
period. Estimated GFR was calculated using the updated
Schwartz formula (Eq. 2) [26]:
eGFR ¼ 0:413  length
Scr
 
ð2Þ
where eGFR is estimated GFR (mL/min/1.73 m2), length is
body length (cm), and Scr is serum creatinine (mg/dL,
modified kinetic Jaffe method). Serum creatinine concen-
trations obtained at B3 days postnatal age were considered
to reflect maternal renal function and were excluded from
analysis. Continuous covariates were normalized to popu-
lation mean values and were tested for inclusion in linear,
power, and exponential functional forms [27]. Categorical
covariates were tested for inclusion using additive shift
models. Potential covariates were tested using stepwise
forward selection followed by stepwise backward elimi-
nation. Changes in OFV were considered significant at
p\ 0.05 (Chi-square distribution, 1 df, DOFV[ 3.84)
during forward selection, and p\ 0.01 (DOFV[ 6.63)
during backward elimination [28].
2.4 Internal Model Evaluation
Stability of the final covariate model was evaluated by
nonparametric bootstrap [29]. PDx-Pop was used to gen-
erate 1000 bootstrap datasets by random sampling with
replacement from the original model-building dataset.
Additionally, normalized prediction distribution errors
(NPDEs) based on 1000 simulations were calculated in
NONMEM, and plots were generated for the NPDE dis-
tribution and NPDEs versus time, population-predicted
concentrations, and influential covariates [30]. Finally,
numerical and visual predictive checks were performed to
compare observed paracetamol concentrations with con-
centrations obtained from model-based simulations of
1000 datasets [31]. Predictive checks were performed
using Perl-speaks-NONMEM 4.2.0 (PsN, http://psn.
sourceforge.net) interfaced with Pirana 2.9.0 (http://
pirana-software.com) [32]. Visual predictive check data
were prediction corrected [33] and binned based on
observation counts.
2.5 External Model Evaluation
An external dataset (Study 2) was used to assess the gen-
eralizability of the final covariate model [6]. Predictive
performance was assessed as suggested by Sheiner and
Beal [34] to quantify bias and precision. Confidence
intervals for central tendency measures of bias and preci-
sion were obtained via bootstrap techniques (n = 2000).
Additionally, external evaluation procedures based on
NPDEs and numerical and visual predictive checks were
performed as described in Sect. 2.4.
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3 Results
Key information from Studies 1 and 2 is summarized in
Table 1. The model-building dataset (Study 1) consisted
of 267 observations from 35 patients (median 8; range
3–11 concentrations/patient). Of these 267 paracetamol
concentrations, one measurement was less than the assay
LLOQ and was excluded from the analysis. Six mea-
surements (2 %) were implausible (e.g. peak concentra-
tions observed at trough collection times) and were also
excluded. Thus, 260 paracetamol concentrations were
used for the development and internal evaluation of the
population pharmacokinetic model. The external dataset
(Study 2) consisted of 436 paracetamol concentrations
from 60 patients (median 7; range 2–11 concentra-
tions/patient). The proportion of patients who received
intravenous paracetamol for postoperative analgesia ver-
sus a medical condition was similar in the two studies;
however, the types of surgery and specific medical indi-
cations were more diverse in Study 2. The two studies
also had similar proportions of preterm and full-term
neonates but the percentage of extremely preterm neo-
nates in Study 1 was more than three times that in Study
2 (29 vs. 8 %).
Table 1 Study information for the model-building and external evaluation datasets
Study 1, model-building dataset Study 2, external dataset (PARANEO) [6]
NCT identifier 01328808 00969176
Study description Phase II/III, multiple-dose study
of intravenous paracetamol
Phase II/III, multiple-dose study of
intravenous paracetamol
Study drug Ofirmev (10 mg/mL) Paracetamol Sintetica (10 mg/mL)
Sampling route Arterial Arterial
Analytical method HPLC–MS/MS HPLC–UV
Subjects 35 neonates 60 neonates
Samples (n) 260 436
N per subject [median (range)] 8 (3–11) 7 (2–11)
Primary indication for intravenous paracetamol [n (%)]
Postoperative analgesia 19 (54) 33 (55)
Cardiac surgery 19 (54) 15 (25)
Thoracic surgery 0 (0) 11 (18)
Abdominal surgery 0 (0) 6 (10)
Other 0 (0) 1 (2)
Medical conditions 16 (46) 27 (45)
Alprostadil administration 0 (0) 8 (13)
Procedural/respiratory 16 (46) 8 (13)
Traumatic pain 0 (0) 5 (8)
Fever 0 (0) 3 (5)
Other 0 (0) 3 (5)
Gestational status [n (%)]
Extreme preterm (\28 weeks’ GA) 10 (29) 5 (8)
Preterm (\37 weeks’ GA) 17 (49) 28 (47)
Full-term (37–42 weeks’ GA) 18 (51) 32 (53)
Current body weighta (kg) by gestational age subgroup [median (range)]
Extreme preterm (\28 weeks’ GA) 0.69 (0.55–1.30) 0.90 (0.61–1.41)
Preterm (\37 weeks’ GA) 0.96 (0.46–2.80) 2.08 (0.61–3.66)
Full-term (37–42 weeks’ GA) 3.16 (2.70–4.20) 3.22 (1.80–4.30)
Postnatal agea (days) by gestational age subgroup [median (range)]
Extreme preterm (\28 weeks’ GA) 10 (1–26) 17 (6–24)
Preterm (\37 weeks’ GA) 9 (1–26) 6 (1–27)
Full-term (37–42 weeks’ GA) 6 (2–12) 2 (1–10)
GA gestational age, HPLC high-performance liquid chromatography, MS/MS tandem mass spectrometry, NCT National Clinical Trial, PARA-
NEO Paracetamol in Neonates, UV ultraviolet detection
a On the day of the first paracetamol dose
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Demographic characteristics of the model-building
study population are summarized in Tables 2 and 3 for
continuous and categorical variables, respectively. The
median gestational age was 37 weeks (range 23–41), and
most study subjects (66 %) received the first paracetamol
dose within 1 week after birth. Median body weight at the
time of the first paracetamol dose was 2.80 kg (range
0.46–4.20). Body length was missing from one patient
record, which precluded calculation of BMI and estimated
GFR for that subject. Total bilirubin measurements were
not obtained within the requisite timeframe for 13 subjects.
Additionally, two subjects did not have serum creatinine
measurements obtained within the requisite timeframe, and
three subjects had serum creatinine measurements that
were excluded because they were considered to reflect
maternal renal function (postnatal age B3 days).
The model-building dataset was best described by a one-
compartment structural model with first-order elimination.
A two-compartment model had a higher BIC than a com-
parable one-compartment model (847.6 vs. 841.7) and
provided no visual improvement in standard diagnostic
plots relative to a one-compartment model. Additionally,
condition numbers of 14 and 161,905 were obtained,
respectively, for comparable one- and two-compartment
models, which suggested that the two-compartment model
was an over-parameterized representation of the data [23].
When additive, proportional, and combined additive and
proportional error functions were tested for characteriza-
tion of RUV, the proportional function produced the lowest
OFV and was selected for inclusion in the model (Eq. 3):
Yij ¼ Ymij þ Ymij  eij ð3Þ
where Yij is the observed paracetamol concentration for the
ith individual at time j, Ymij is the model-predicted parac-
etamol concentration, and eij is a normally distributed
random error with a mean of zero and a variance of r2.
During testing of potential covariates, subjects with
missing information for a covariate undergoing evaluation
were excluded from both the base and covariate models
being tested. Current body weight was found to have a
strong influence on paracetamol pharmacokinetics. Current
body length and BMI were also tested as markers of body
size, but their performance was inferior to that of weight.
Postnatal age was identified as a significant covariate on
clearance during the forward selection process but it failed
to meet the criterion for inclusion as a covariate during
backward elimination. Additionally, the final forward
selection step showed that total bilirubin was a significant
covariate on paracetamol clearance and volume of distri-
bution: decreases in OFV ranged from 4.2 to 7.3,
depending on the pharmacokinetic parameter and
Table 2 Subject demographics
for continuous covariates tested
in the model-building dataset
Characteristic N Mean SD CV Median Range
Current body weighta (kg) 35 2.30 1.22 0.530 2.80 0.46–4.20
Current body lengtha (cm) 34 43.4 9.15 0.211 47.5 25.0–56.0
BMI (kg/m2) 34 11.1 2.91 0.263 12.0 6.04–16.7
Gestational age (weeks) 35 33.6 6.57 0.196 37 23–41
Postnatal agea (days) 35 7.49 5.73 0.766 6 1–26
Postmenstrual agea (weeks) 35 34.6 6.28 0.181 37.6 23.1–41.6
Total bilirubin (mg/dL) 22 6.65 4.88 0.734 4.8 0.9–17.5
Serum creatinineb (mg/dL) 30 0.707 0.242 0.342 0.7 0.3–1.1
Estimated GFRc (mL/min/1.73 m2) 29 30.1 16.6 0.551 24.1 12.6–70.9
BMI body mass index, CV coefficient of variation, GFR glomerular filtration rate, SD standard deviation
a On the day of the first paracetamol dose
b Serum creatinine concentrations obtained at B3 days postnatal age were considered to reflect maternal
renal function and were excluded from the analysis
c Estimated GFR was calculated using the updated Schwartz formula (Eq. 2) [26]
Table 3 Subject demographics for categorical covariates tested in
the model-building dataset
Characteristic N (%)
Sex
Male 20 (57)
Female 15 (43)
Race
White/Caucasian 16 (46)
Black/African American 14 (40)
American Indian/Alaska Native 1 (3)
Asian 1 (3)
Declined to respond 3 (9)
Ethnicity
Non-Hispanic 24 (69)
Hispanic 8 (23)
Declined to respond 3 (9)
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functional form of the covariate. However, total bilirubin
was not included in the model due to the fact that these
laboratory values were unavailable for 37 % of the study
subjects. None of the other potential covariates met the
criterion for inclusion at the final forward selection step.
Based on OFV, a power function of mean-centered weight
best described the relationship between weight and parac-
etamol pharmacokinetic parameters (Eq. 4):
hi ¼ hpop  WTi
2:30
 hcov
egi ð4Þ
where hi is the individual model-predicted pharmacokinetic
parameter (e.g. clearance) for an individual with current
body weight of WTi (kg), hpop is the population mean for
the pharmacokinetic parameter h when current body weight
is equal to the mean current body weight of the study
population, 2.30 is the mean current body weight of the
study population (kg), hcov is the covariate effect, and gi is
the between-subject random effect for the ith individual on
the pharmacokinetic parameter h. In the final backward
elimination step, removal of weight on clearance and vol-
ume of distribution increased the OFV by 65.5 and 81.8,
respectively. The hcov exponent in Eq. 4 was first estimated
to be 1.07 and 0.892 for clearance and volume of distri-
bution, respectively. To simplify the final model equations,
these values were rounded and fixed at 1.1 and 0.9, which
caused a trivial change in OFV (increase of 0.2).
Parameter estimates derived from the final covariate
model are provided in Table 4. Overall, model parameters
were estimated with reasonably good precision, and boot-
strap estimates agreed well with those obtained from the
final covariate model. Only one of the 1000 bootstrap
datasets (0.1 %) failed to minimize during parameter esti-
mation. Standard diagnostic plots are also provided to
illustrate the fit of the final covariate model. Plots of
observed versus population- and individual-predicted
paracetamol concentrations are provided in Fig. 1, and
conditional weighted residuals versus time and population-
predicted paracetamol concentrations are shown in Fig. 2.
Simulation-based visualizations of model appropriate-
ness were generated with NPDEs and a visual predictive
check. The mean NPDE from the model-building dataset
was 0.0485, and the variance was 0.935. These values were
not significantly different from the expected mean of 0
(Wilcoxon signed-rank test, p = 0.231) and variance of 1
(Fisher variance test, p = 0.476) (Fig. 3a). Additionally,
there were no visible trends in NPDEs when plotted against
time since previous dose (Fig. 3c), population-predicted
paracetamol concentration (Fig. 3e), and current body
weight (Fig. 3g). The visual predictive check demonstrated
good agreement between observed paracetamol concen-
trations and model-based simulations (Fig. 4a), and a
numerical predictive check determined that 92.7 % of the
observations fell within the simulation-based 90 % pre-
diction interval.
Key subject characteristics for the external dataset are
summarized in Tables 1 and 5. Compared with the model-
building dataset, the external dataset had a lower propor-
tion of extremely preterm neonates and tended toward
younger postnatal ages. Additionally, whereas the model-
building dataset was obtained from a US-based study with
fairly even representation of White/Caucasian and Black/
African American races, the external dataset was derived
from a Belgian study with predominantly White/Caucasian
subjects [6].
Bias (prediction error) and precision (absolute prediction
error) were quantitated by applying the final covariate model
to the external dataset. Population-predicted concentrations
from the model tended to be slightly higher than observed
values (Table 6). The mean NPDE from the external dataset
Table 4 Parameter estimates for the final covariate model
Parameter Model fit Bootstrap 95 % CIa
Estimated value
(%RSE)
BSV (x2), as % CV
(% RSE)
Estimated
value
BSV (x2),
as % CV
CL (L/h)b 0.348 (5.5) 30.8 (19.9) 0.311–0.387 23.9–36.2
Effect of weightc 1.1 fixed 1.1 fixed
Vd (L)
b 2.46 (3.5) 14.3 (51.2) 2.29–2.64 0.1–19.9
Effect of weightc 0.9 fixed 0.9 fixed
Proportional residual unexplained
variability (r2)
0.0576 (20.8) 0.0373–0.0844
BSV between-subject variability, CI confidence interval, CL total body clearance, % CV percent coefficient of variation, % RSE percent relative
standard error, Vd volume of distribution
a Bootstrap success rate was 99.9 % (n = 1000)
b At the mean current body weight of the study population (2.30 kg)
c Exponent on mean-centered weight, i.e. the covariate effect (hcov) in Eq. 4
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was -0.00772, which was not significantly different from
the expected mean of 0 (Wilcoxon signed-rank test,
p = 0.178), but the NPDE variance from the external dataset
was 0.516, which was lower than the expected variance of 1
(Fisher variance test, p = 2.09 9 10-18). Thus, the final
covariate model overpredicted the amount of variability in
the external dataset (Fig. 3b). However, the NPDE showed
no bias when plotted against time since previous dose
(Fig. 3d), population-predicted paracetamol concentration
(Fig. 3f), and current body weight (Fig. 3h). Additionally, a
visual predictive check demonstrated reasonably good
agreement between paracetamol concentration observations
from the external dataset and model-based simulations
(Fig. 4b). Finally, the numerical predictive check deter-
mined that 95.9 % of the observations fell within the 90 %
prediction interval, which also indicated that the model
overestimated the amount of variability in the external
dataset.
4 Discussion
Previous neonatal studies of intravenous paracetamol and
propacetamol, a prodrug that is rapidly hydrolyzed by
plasma esterases to form paracetamol, have used one- [22,
35, 36] and two-compartment [6, 8] models. In the present
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study, the model-building dataset was best described by a
one-compartment model. At the mean current body weight
of the study population, the final covariate model gave
parameter estimates of 0.151 L/h/kg (0.348 L/h/2.30 kg)
and 1.07 L/kg (2.46 L/2.30 kg) for clearance and volume of
distribution, respectively. Clearance estimates from earlier
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Fig. 3 NPDEs of paracetamol plasma concentrations from the
model-building dataset (a, c, e, g) and the external evaluation dataset
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neonatal studies ranged from 0.090–0.21 L/h/kg, depending
in part on gestational, postmenstrual, or postconceptional
age [6, 8, 22, 35, 36]. Previously reported volume of dis-
tribution estimates were slightly lower than those observed
here, with values ranging from 0.56–0.76 L/kg [8, 35].
To compare the neonatal pharmacokinetic parameter
estimates from the present study with adult values, esti-
mates can be extrapolated to a standard 70 kg adult using
allometric scaling. If allometric exponents of 0.75 and 1 are
applied to the clearance and volume of distribution terms,
respectively [37], this yields values of 4.51 L/h/70 kg for
clearance and 74.9 L/70 kg for volume of distribution.
These values are consistent with allometrically standard-
ized neonatal estimates from prior studies of both intra-
venous [6, 22, 36] and enteral [13, 38] paracetamol. In
neonates, paracetamol clearance values are approximately
one-quarter to one-third of typical adult values [39], and
the relatively low neonatal clearance can be attributed to
incomplete maturation of hepatic drug metabolism path-
ways [14, 40–42].
Current body weight was the only covariate that met
criteria for inclusion in the final model. Previous popula-
tion pharmacokinetic studies found weight, as a correlate of
body size, was the major covariate influencing intravenous
paracetamol pharmacokinetics in neonates [6, 22, 36].
Postmenstrual age [6, 36], postconceptional age [22], and
unconjugated bilirubin [6, 36] have also been shown to
have minor effects on neonatal clearance of intravenous
paracetamol but these characteristics were not identified as
significant covariates in the present study. The current
study was expected to have reasonably good power to
detect an effect of postmenstrual age on clearance because
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of the final covariate model for
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dataset. The solid black lines
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percentiles, and the dashed
black lines depict the observed
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b because the density of points
would obscure the percentile
lines and prediction intervals
Table 5 Key subject
demographics from the external
evaluation dataset
Characteristic N Mean SD CV Median Range
Current body weight (kg) 60 2.62 0.894 0.341 2.71 0.61–4.30
Gestational age (weeks) 60 35.6 4.34 0.122 37 24–41
Postnatal age (days) 60 6.08 6.85 1.126 3 1–27
Postmenstrual age (weeks) 60 36.5 3.89 0.106 37.4 26.4–42.0
CV coefficient of variation, SD standard deviation
Table 6 Predictive
performance of the final
covariate model when applied to
the external dataset
Concentration (mg/L) Percentage of observed concentration
Median 95 % CI Median 95 % CI
Prediction error 0.911 0.495–1.33 10.1 6.13–14.3
Absolute prediction error 2.22 2.07–2.35 25.3 23.1–28.1
CI confidence interval
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it had a good representation of extreme preterm, preterm,
and full-term neonates (Table 1) and was obtained from
subjects with a fairly wide range of postmenstrual ages
(23.1–41.6 weeks). Given that prior studies in neonates
have found only minor increases in paracetamol clearance
with increasing postmenstrual or postconceptional age, the
failure to identify postmenstrual age as a significant
covariate was not surprising. Indeed, maturation of parac-
etamol clearance appears to be fairly slow up until a
postmenstrual age of 40 weeks and then occurs more
rapidly during the first year of life [42]; therefore, the
ability of this study to detect any age-related covariate
effects was likely limited by the fact that the postnatal age
of most study subjects (66 %) did not exceed 7 days.
During forward covariate selection, total bilirubin was
inversely correlated with clearance, which agrees with
previous findings that high unconjugated bilirubin was
associated with reduced clearance [6, 36]. Physiologically,
these observations can be attributed to the fact that both
paracetamol and bilirubin undergo substantial clearance via
glucuronidation, and concentrations of paracetamol and
unconjugated or total bilirubin are therefore expected to be
correlated. Because the association between total bilirubin
and paracetamol pharmacokinetic parameters was fairly
weak, and these laboratory values were unavailable for
37 % of the study subjects, it was decided that omission of
this covariate from the final model was preferable to the
data imputation that would be required if the covariate was
retained.
Perhaps the most comprehensive study to date on the
pharmacokinetics of intravenous paracetamol in neonates is
the pooled analysis performed by Allegaert et al. [6]. A
subset of that pooled data was used to externally evaluate
the final covariate model reported herein. This external
dataset from the PARANEO trial was selected because the
study design and subject demographics were relatively
consistent with those of the study from which the model-
building dataset was obtained. The final covariate model
demonstrated acceptable bias and precision when applied to
the external dataset (Table 6). The most substantial differ-
ence between model predictions and external data obser-
vations was an overestimation of variability, which was
particularly evident in the NPDEs and numerical and visual
predictive checks. This discrepancy could be attributable to
differences in patient demographics, study design or exe-
cution, or analytical drug quantification. However, given the
gestational age distributions from the two studies, larger
variability might be expected in the model-building dataset,
based on the higher proportion of extremely preterm sub-
jects. Overall, the external evaluation indicated that the final
covariate model performed adequately despite notable study
differences in the proportion of extremely preterm neonates,
postnatal age, racial composition, and geographic location.
One major strength of the present study was the inclu-
sion of a large number of extremely preterm neonates.
Additionally, the final covariate model was successfully
evaluated against a dataset obtained from a similar, inde-
pendent clinical trial—a validation procedure that is rarely
performed in neonatal clinical research. This study
demonstrated that the pharmacokinetics of intravenous
paracetamol can be predicted using body weight in neo-
nates ranging from extreme preterm to full-term gestational
status. This finding reinforces previous work that supported
the use of a simplified neonatal dosing regimen in which
maturational changes in paracetamol pharmacokinetics
could be accommodated using only equivalent per kilo-
gram dosing, without requiring different doses or dosing
intervals dependent on gestational or postmenstrual age [6].
The results of the present study suggest that extension of
such a parsimonious dosing regimen to extremely preterm
neonates may be valid; however, these findings should be
interpreted with caution based on the limitations outlined
below.
Although the number and proportion of extremely pre-
term neonates in this study was substantially higher than in
previous reports, the sample size was still relatively small,
as is often the case for neonatal trials. Additionally, BSV in
the final covariate model remained fairly large, particularly
for clearance (30.8 % CV), and it is possible that other
unmeasured factors could be incorporated as covariates to
further reduce the unexplained BSV. Another important
limitation is related to hepatotoxicity, the principal safety
concern that accompanies use of the drug. Paracetamol-
induced hepatotoxicity is not associated with exposure to
the parent drug per se but rather depends on the amount of
exposure to a relatively minor toxic metabolite, N-acetyl-p-
benzoquinone imine (NAPQI) [43]. In humans, cyto-
chrome P450 (CYP) 2E1 is predominantly responsible for
the conversion of paracetamol to NAPQI [43]. Hepatic
expression of CYP2E1 increases during the neonatal per-
iod, approaching adult values by approximately 90 days
postnatal age [44]. Additionally, glucuronidation accounts
for the majority of paracetamol clearance in adults, but
glucuronidation capacity is immature in neonates [14, 45].
Thus, maturational changes in hepatotoxicity risk may not
be reflected in the pharmacokinetics of the parent drug, and
the pharmacokinetics of paracetamol metabolites should be
studied to address this safety concern more thoroughly.
Finally, although this study provides critical information
regarding the pharmacokinetics of intravenous paracetamol
in neonates, it should be noted that pharmacodynamic data
for paracetamol are still quite limited in this patient pop-
ulation [46]. Further studies are needed to determine
appropriate pharmacodynamic targets, which may vary by
indication (e.g. analgesia, antipyresis, or patent ductus
arteriosus closure) [47, 48].
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5 Conclusions
A one-compartment model successfully characterized
the pharmacokinetics of intravenous paracetamol in
preterm and term neonates. Clearance and volume of
distribution increased with body weight, and weight was
the principal predictor of intravenous paracetamol
pharmacokinetics in extremely preterm to full-term
neonates. An external evaluation supported the gener-
alizability of the final covariate model to other similar
patient populations.
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